The Drug Controller General of India (DCGI) Thursday suspended manufacturing and import of the anti-diabetic drug Rosiglitazone.

The US FDA too had recently restricted its use after data suggested continued use of rosiglitazone (Avandia) could increase the risk of cardiovascular problems.